Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 7
1962 14
1963 42
1964 51
1965 52
1966 31
1967 42
1968 35
1969 46
1970 31
1971 50
1972 34
1973 39
1974 46
1975 28
1976 48
1977 26
1978 25
1979 33
1980 27
1981 33
1982 29
1983 26
1984 23
1985 22
1986 24
1987 21
1988 23
1989 21
1990 16
1991 15
1992 19
1993 20
1994 20
1995 26
1996 15
1997 22
1998 15
1999 22
2000 29
2001 16
2002 20
2003 15
2004 13
2005 18
2006 28
2007 22
2008 31
2009 34
2010 30
2011 46
2012 33
2013 32
2014 32
2015 59
2016 54
2017 48
2018 40
2019 55
2020 69
2021 62
2022 64
2023 61
2024 49
2025 48
2026 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,040 results

Results by year

Filters applied: . Clear all
Page 1
Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D, Sarao V, Diplotti L, Samassa F, Lanzetta P. Veritti D, et al. Expert Opin Pharmacother. 2017 Oct;18(14):1507-1516. doi: 10.1080/14656566.2017.1363182. Epub 2017 Aug 9. Expert Opin Pharmacother. 2017. PMID: 28764565 Review.
Fluocinolone acetonide intravitreal implant is a non-erodible implant approved for the treatment of diabetic macular edema (DME) insufficiently responsive to available therapies. Areas covered: The injectable intravitreal implant releases fluocinolone acet …
Fluocinolone acetonide intravitreal implant is a non-erodible implant approved for the treatment of diabetic macular edema (DM …
Fluocinolone acetonide.
ROBINSON HM Jr. ROBINSON HM Jr. Arch Dermatol. 1961 Jan;83:149-51. doi: 10.1001/archderm.1961.01580070155019. Arch Dermatol. 1961. PMID: 13742296 No abstract available.
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN( )): A Review in Diabetic Macular Edema.
Syed YY. Syed YY. Drugs. 2017 Apr;77(5):575-583. doi: 10.1007/s40265-017-0722-4. Drugs. 2017. PMID: 28283896 Review.
ILUVIEN( ) releases fluocinolone acetonide at an initial rate of 0.25 g/day (average rate 0.2 g/day) and lasts 36 months. ...Available data indicate that fluocinolone acetonide intravitreal implant 0.19 mg is a useful option for the treatment of DME …
ILUVIEN( ) releases fluocinolone acetonide at an initial rate of 0.25 g/day (average rate 0.2 g/day) and lasts 36 months. .. …
FLUOCINOLONE ACETONIDE IMPLANT IN THE TREATMENT OF RETINAL ANGIOPATHY MACULAR EDEMA IN ATTRV30M PATIENTS.
Quintas Cales S, Bragança FC, Marques JH, Coelho JM, Menéres MJ, Beirão JM. Quintas Cales S, et al. Retina. 2025 Oct 1;45(10):1967-1973. doi: 10.1097/IAE.0000000000004542. Retina. 2025. PMID: 40456135
PURPOSE: To evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 g/day fluocinolone acetonide, ILUVIEN) in macular edema due to retinal amyloid angiopathy in patients with hereditary transthyretin amyloidosis associated wi …
PURPOSE: To evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 g/day fluocinolone ac …
Fluocinolone acetonide intravitreal implant (Iluvien ): in diabetic macular oedema.
Sanford M. Sanford M. Drugs. 2013 Feb;73(2):187-93. doi: 10.1007/s40265-013-0010-x. Drugs. 2013. PMID: 23335133 Review.
Fluocinolone acetonide intravitreal implant (Iluvien ) is an injectable, non-erodible, corticosteroid implant that is approved in several European countries for the treatment of chronic diabetic macular oedema (DMO). ...Fluocinolone acetonide intravitr …
Fluocinolone acetonide intravitreal implant (Iluvien ) is an injectable, non-erodible, corticosteroid implant that is approved …
HAND ECZEMA.
BETTLEY FR. BETTLEY FR. Br Med J. 1964 Jul 18;2(5402):151-5. doi: 10.1136/bmj.2.5402.151. Br Med J. 1964. PMID: 14150887 Free PMC article. No abstract available.
Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis.
Mahmud H, Ahmad TR, Gonzales JA, Stewart JM. Mahmud H, et al. Ocul Immunol Inflamm. 2023 Oct;31(8):1603-1607. doi: 10.1080/09273948.2022.2076131. Epub 2022 Jul 6. Ocul Immunol Inflamm. 2023. PMID: 35793136
PURPOSE: To evaluate the efficacy of the fluocinolone acetonide intravitreal implant (Yutiq) as monotherapy for uveitis. DESIGN: Retrospective cohort study. ...The remaining five eyes (26%) required additional intraocular treatments. CONCLUSION: The fluocinolone …
PURPOSE: To evaluate the efficacy of the fluocinolone acetonide intravitreal implant (Yutiq) as monotherapy for uveitis. DESIG …
Intravitreal fluocinolone acetonide implant (ILUVIEN ) for diabetic macular oedema: a literature review.
Massa H, Nagar AM, Vergados A, Dadoukis P, Patra S, Panos GD. Massa H, et al. J Int Med Res. 2019 Jan;47(1):31-43. doi: 10.1177/0300060518816884. Epub 2018 Dec 16. J Int Med Res. 2019. PMID: 30556449 Free PMC article. Review.
In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN …
In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-v …
Fluocinolone acetonide for the treatment of diabetic macular edema.
Haritoglou C, Mayer W, Wolf A. Haritoglou C, et al. Expert Rev Clin Pharmacol. 2016;9(3):367-74. doi: 10.1586/17512433.2016.1133287. Epub 2016 Jan 15. Expert Rev Clin Pharmacol. 2016. PMID: 26681198 Review.
At present two intravitreal steroid inserts are approved for the treatment of DME containing either dexamethasone or fluocinolone acetat (FA) as a pharmacological compound. The non degradable intravitreal FA insert releases 0.2 g FA per day (Iluvien, Alimera Sciences). .. …
At present two intravitreal steroid inserts are approved for the treatment of DME containing either dexamethasone or fluocinolone ace …
2,040 results